Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. A Single-Arm, Multicenter Clinical Trial

NCT06047535 is registered in ClinicalTrials.gov with SciClone Pharmaceuticals as lead sponsor.

NCT NCT06047535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06047535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. A Single-Arm, Multicenter Clinical Trial
Lead sponsor
SciClone Pharmaceuticals
Phase
Phase 4
Overall status
Not yet recruiting
Start date
October 31, 2023
Completion date
August 15, 2027
Enrollment
62 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma